Vertex’s Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth’s Optum Rx Formularies
Where Today's News Shapes Tomorrow
